Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Joseph Truitt is Director at Larimar Therapeutics. OQRO lists 3 transactions filed with the SEC under this name, the latest on Nov 12, 2026, each linked to the official Form 4.
Director
Disclosures on record
3
Companies involved
2
1 purchase disclosed. $1,000 placed after each of the 1 purchases disclosed since 2025-11-14 would be worth $1K today ($1K put in); the same in the S&P 500 (SPY): $1K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Larimar TherapeuticsLRMR
2 disclosures · May 2026 – Nov 2026 · 1 bought
Nov 11, 2026Bought~$9.8Kdisclosed Nov 12
DetailsOfficial recordMay 19, 202655Kdisclosed May 20
DetailsOfficial recordSep 9, 2026148Kdisclosed Sep 10
DetailsOfficial recordAs of the latest filing on , Joseph Truitt reported holding 6,250 shares of Larimar Therapeutics (LRMR), worth about $19K at the last close of $3 (Nov 13, 2026). In the last 12 months, Joseph Truitt bought $9.8K in 1 open-market purchase.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Larimar Therapeutics LRMR | 6,250 | 6,250 direct | $3 | $19K | Nov 11, 2026 |
Is this Joseph Truitt’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Joseph Truitt bought shares on the open market in 2023 and 2026.
Joseph Truitt reported 2 open-market purchases and 0 sales since 2023; purchases in 2 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $9.8K1×1 trade | — |
| 2023 | $10K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 11, 2026, Joseph Truitt reported holding 6,250 shares of Larimar Therapeutics (LRMR). At the last close of $3 on Nov 13, 2026, that is about $19K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Joseph Truitt reported 1 open-market purchase worth $9.8K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Joseph Truitt bought shares on the open market in 2023 and 2026.
In SEC filings since 2023: the latest open-market purchase is from 2026; no open-market sale is on record.
Larimar Therapeutics (LRMR), from 2023 to 2026: 2 purchases and 0 sales.
Joseph Truitt reported 2 open-market purchases and 0 sales here, 2023 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
